ASCO17 - Cleveland Clinic

Tag debug info: client: {"assets":{},"datasets":{},"live":{},"projects":{},"users":{},"observable":{"assets":{},"datasets":{},"live":{},"projects":{},"users":{}}}
Now: 1770728754529
Cache Key: cqdTagPageBySlug:asco17
fetchCache[cqdTagPageBySlug:asco17].expirationTime: falsey
fetchCache[cqdTagPageBySlug:asco17]. seconds remaining: falsey
All fetchCache expiration times:
-- Key: cqdNotFoundPage, seconds remaining: -80482
-- Key: cqdTagPageBySlug:cell-therapy, seconds remaining: -534412
-- Key: cqdPostsByTag:cqd-migrated-tag-23286,2,10, seconds remaining: -534325
-- Key: cqdTagPageBySlug:combined-procedure, seconds remaining: -514766
-- Key: cqdPostsByTag:cqd-migrated-tag-9188,1,10, seconds remaining: -514699
-- Key: cqdTagPageBySlug:coronary-artery-disease-cad, seconds remaining: -80482
-- Key: cqdPostsByTag:cqd-migrated-tag-17044,1,10, seconds remaining: -80402
conditions:
-- false,
-- NA,
-- NA,
-- NA
-- false
Cache miss for key cqdTagPageBySlug:asco17 - retrieving from Sanity
CCCache.dataFetchCount: 65
Cache cleanup seconds remaining: 30000

Tag: ASCO17

Time to Treat is Increasing, Associated with Worsened Survival

Study Suggests Some Small Cell Lung Cancer Patients Benefit from Immune Checkpoint Inhibitor

Trial Finds Maximum Tolerable Dose for Combination Therapy for Metastatic Renal Cell Carcinoma Patients

Maximum Tolerable Doses for Adding Cell Checkpoint Inhibitor to Standard of Care for Glioblastoma Patients

A Novel Approach: Aggressive Chemotherapy Regimen Before Surgery in Resectable Pancreatic Adenocarcinoma